CGON: FDA BLA Acceptance Catalyst Sparks Rally | +8.4% in 2 Days
The opportunity
We flagged CGON at a snapshot price of $54.92 on 2026-06-10. The stock was sitting near a technical base of $55.53 with its RSI deeply oversold at 29.9. While the broader market waited on the sidelines, we identified an impending high-impact catalyst: the expected FDA decision on accepting the rolling Biologics License Application (BLA) for Cretostimogene, alongside its Priority or Standard Review designation.
The forecast
The path forward hinged on this binary regulatory milestone. A formal BLA acceptance and potential Priority Review was projected to serve as a major de-risking event, clearing the way for a relief rally toward the bull target of $68.00 (aligned with the 50-day SMA). Conversely, a Refuse to File (RTF) letter posed a downside risk, threatening to drag the high-beta stock down to its 200-day SMA at $46.00.
The payoff
By the target date of 2026-06-12, CGON climbed to $59.56, delivering an 8.4% return (8.45% realized return) from our snapshot entry. The rally was fueled by positive investor sentiment following management presentations at the Jefferies and Goldman Sachs Global Healthcare Conferences, where the CEO highlighted upcoming clinical milestones, Phase 3 data readouts, and commercial preparations for Cretostimogene in non-muscle invasive bladder cancer (NMIBC).
No Data